Dianthus Therapeutics Inc. (DNTH) Financial Statements (2025 and earlier)

Company Profile

Business Address 300 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments360,707377,036173,718189,87077,59378,206
Cash and cash equivalents314,169329,724132,325157,28262,63348,523
Short-term investments46,53847,31241,39332,58814,96029,683
Restricted cash and investments      1,780
Receivables840435294751  
Prepaid expense20347259620  
Disposal group, including discontinued operation      541
Other undisclosed current assets3,9372,9832,8438121,0452,914
Total current assets:365,687380,926177,451191,45378,63883,441
Noncurrent Assets
Operating lease, right-of-use asset442530615698  
Property, plant and equipment189195185195  
Long-term investments and receivables      
Long-term investments      
Other undisclosed noncurrent assets2,6418111,154116  
Total noncurrent assets:3,2721,5361,9541,009  
TOTAL ASSETS:368,959382,462179,405192,46278,63883,441
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,5528,4599,11412,5664,0344,592
Accounts payable3,6952,6122,6101,3698131,080
Accrued liabilities5,8575,8476,50411,1973,2213,512
Deferred revenue100100100100  
Other undisclosed current liabilities377400417413 1,390
Total current liabilities:10,0298,9599,63113,0794,0345,982
Noncurrent Liabilities
Liabilities, other than long-term debt7128169041,002  
Deferred revenue682719736745  
Operating lease, liability 3097168257  
Total noncurrent liabilities:7128169041,002  
Total liabilities:10,7419,77510,53514,0814,0345,982
Equity
Equity, attributable to parent358,218372,687168,870178,38174,60477,459
Common stock292915156161
Additional paid in capital479,004475,856258,231257,230509,029508,613
Accumulated other comprehensive income (loss)(37)(27)47(4)(3)(16)
Accumulated deficit(120,778)(103,171)(89,423)(78,860)(434,483)(431,199)
Total equity:358,218372,687168,870178,38174,60477,459
TOTAL LIABILITIES AND EQUITY:368,959382,462179,405192,46278,63883,441

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues   (2,369)9243,300 
Other income     3,300 
Gross profit:    9243,300 
Operating expenses(24,067)(18,718)(13,413)(16,683)(7,375)(32,130)
Other undisclosed operating income (loss)1,863874457 (3,300) 
Operating loss:(22,204)(17,844)(12,956)(15,759)(7,375)(32,130)
Nonoperating income4,5974,0962,393996 336
Investment income, nonoperating      336
Loss from continuing operations:(17,607)(13,748)(10,563)(14,763)(7,375)(31,794)
Other undisclosed net income      2,624
Net loss:(17,607)(13,748)(10,563)(14,763)(7,375)(29,170)
Other undisclosed net income attributable to parent     4,091 
Net loss available to common stockholders, diluted:(17,607)(13,748)(10,563)(14,763)(3,284)(29,170)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(17,607)(13,748)(10,563)(14,763)(7,375)(29,170)
Other comprehensive income (loss)(10)(74) 15  
Other undisclosed comprehensive income   208   
Comprehensive loss:(17,617)(13,822)(10,355)(14,748)(7,375)(29,170)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   (157) 4,104165
Comprehensive loss, net of tax, attributable to parent:(17,617)(13,822)(10,512)(14,748)(3,271)(29,005)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: